Two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule, research shows. Since high coverage and compliance rates can be difficult to achieve with the current three-dose HPV vaccineregimen, several studies have looked at the possibility of reducing the number of doses. Proof-of-principle that a two-dose schedule can provide sufficient protection against cervical cancer came initially from a study performed in Costa Ric...
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/b...
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/b...